

LABORATORY CORP OF AMERICA HOLDINGS
Form 10-Q
August 03, 2006

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark
One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2006

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____ to ____

Commission file number 1-11353

**LABORATORY CORPORATION OF
AMERICA HOLDINGS**

(Exact name of registrant as specified in its charter)

Delaware

13-3757370

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification No.)

**358 South Main Street,
Burlington, North Carolina**

27215

(Address of principal executive offices)

(Zip Code)

(Registrant's telephone number, including area code) (336) 229-1127

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of "accelerated filer" and "large accelerated filer" in Rule 12b-2 of the Exchange Act.

Large accelerated filer Accelerated filer Non-accelerated filer

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act. Yes No

Edgar Filing: LABORATORY CORP OF AMERICA HOLDINGS - Form 10-Q

The number of shares outstanding of the issuer's common stock is 125.2 million shares, net of treasury stock as of July 26, 2006.

INDEX

PART I. FINANCIAL INFORMATION

Item 1 Financial Statements:

Condensed Consolidated Balance Sheets
June 30, 2006 and December 31, 2005

Condensed Consolidated Statements of Operations
Three and six month periods ended June 30, 2006 and 2005

Condensed Consolidated Statements of Changes in Shareholders' Equity
Six months ended June 30, 2006 and 2005

Condensed Consolidated Statements of Cash Flows
Six months ended June 30, 2006 and 2005

Notes to Unaudited Condensed Consolidated Financial Statements

Item 2 Management's Discussion and Analysis of
Financial
Condition and Results of Operations

Item 3 Quantitative and Qualitative Disclosures about Market Risk

Item 4 Controls and Procedures

PART II. OTHER INFORMATION

Item 1 Legal Proceedings

Item 1A Risk Factors

Item 2 Changes in Securities, Use of Proceeds and Issuer Purchases of Equity Securities

Edgar Filing: LABORATORY CORP OF AMERICA HOLDINGS - Form 10-Q

Item 4 Submission of Matters to a Vote of Security Holders

Item 6 Exhibits

2

PART I FINANCIAL INFORMATION

Item 1. Financial Statements

LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS(in millions)
(unaudited)

	June 30, 2006	December 31, 2005
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 16.6	\$ 45.4
Short-term investments	185.7	17.7
Accounts receivable, net	537.0	493.4
Supplies inventories	76.2	65.4
Prepaid expenses and other	38.3	37.2
Deferred income taxes	37.7	43.2
	<hr/>	<hr/>
Total current assets	891.5	702.3
Property, plant and equipment, net	370.4	381.5
Goodwill, net	1,476.4	1,477.0
Intangible assets, net	621.7	645.7
Investments in joint venture partnerships	603.9	578.9
Other assets, net	84.8	90.4
	<hr/>	<hr/>
Total assets	\$ 4,048.7	\$ 3,875.8
LIABILITIES AND SHAREHOLDERS' EQUITY		
Current liabilities:		
Accounts payable	\$ 154.1	\$ 116.2
Accrued expenses and other	227.0	227.3
Short term borrowings and current portion of long-term debt	549.9	544.6
	<hr/>	<hr/>
Total current liabilities	931.0	888.1
Long-term debt, less current portion	603.3	604.5
Deferred income taxes	416.8	408.9
Other liabilities	87.5	88.6
	<hr/>	<hr/>
Total liabilities	2,038.6	1,990.1
Commitments and contingent liabilities	--	--
Shareholders' equity:		
Common stock, 125.1 and 126.5 shares outstanding at June 30, 2006 and December 31, 2005, respectively	14.7	14.8
Additional paid-in capital	1,227.2	1,339.7
Retained earnings	1,554.6	1,336.3
Less common stock held in treasury	(891.6)	(888.5)
Unearned restricted stock compensation	--	(6.9)
Accumulated other comprehensive earnings	105.2	90.3
	<hr/>	<hr/>
Total shareholders' equity	2,010.1	1,885.7

Edgar Filing: LABORATORY CORP OF AMERICA HOLDINGS - Form 10-Q

	<u>June 30,</u>	<u>December 31,</u>
Total liabilities and shareholders' equity	\$ 4,048.7	\$ 3,875.8

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

3

LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in millions, except per share data)
(unaudited)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2006	2005	2006	2005
Net sales	\$ 903.7	\$ 853.3	\$ 1,782.2	\$ 1,652.4
Cost of sales	510.9	488.4	1,016.7	949.2
Gross profit	392.8	364.9	765.5	703.2
Selling, general and and administrative expenses	190.2	178.7	381.1	347.3
Amortization of intangibles	13.0	13.1	26.0	25.2
Operating income	189.6	173.1	358.4	330.7
Other income (expenses):				
Investment loss	--	(3.1)	--	(3.1)
Interest expense	(11.6)	(8.6)	(23.5)	(17.1)
Income from joint venture partnerships	17.9	13.9	33.3	27.6
Investment income	1.2	0.3	1.6	0.8
Other, net	(1.2)	0.2	(1.8)	(0.2)
Earnings before income taxes	195.9	175.8	368.0	338.7
Provision for income taxes	79.5	69.8	149.7	136.1
Net earnings	\$ 116.4	\$ 106.0	\$ 218.3	\$ 202.6
Basic earnings per common share	\$ 0.94	\$ 0.79	\$ 1.75	\$ 1.51
Diluted earnings per common share	\$ 0.87	\$ 0.74	\$ 1.62	\$ 1.41

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY
(in millions)
(unaudited)

	Common Stock	Additional Paid-in Capital	Retained Earnings	Treasury Stock	Unearned Restricted Stock Compensation	Accumulated Other Comprehensive Earnings	Total Shareholders' Equity
BALANCE AT DECEMBER 31, 2004	\$ 15.1	\$ 1,504.1	\$ 950.1	\$ (544.2)	\$ (7.5)	\$ 81.7	\$ 1,999.3
Comprehensive earnings:							
Net earnings	--	--	202.6	--	--	--	202.6
Other comprehensive earnings:							
Foreign currency translation adjustments	--	--	--	--	--	(10.8)	(10.8)
Tax effect of other comprehensive loss adjustments	--	--	--	--	--	2.2	2.2
Comprehensive earnings							194.0
Issuance of common stock under employee stock plans	0.1	40.1	--	--	--	--	40.2
Issuance of restricted stock awards	--	7.2	--	--	(7.2)	--	--
Surrender of restricted stock awards	--	--	--	(7.3)	--	--	(7.3)
Cancellation of restricted stock awards	--	(0.3)	--	--	0.3	--	--
Stock compensation	--	2.3	--	--	4.2	--	6.5
Income tax benefit from stock options exercised	--	7.8	--	--	--	--	7.8
Purchase of common stock	--	--	--	(122.1)	--	--	(122.1)
BALANCE AT JUNE 30, 2005	\$ 15.2	\$ 1,561.2	\$ 1,152.7	\$ (673.6)	\$ (10.2)	\$ 73.1	\$ 2,118.4
BALANCE AT DECEMBER 31, 2005	\$ 14.8	\$ 1,339.7	\$ 1,336.3	\$ (888.5)	\$ (6.9)	\$ 90.3	\$ 1,885.7
Comprehensive earnings:							
Net earnings	--	--	218.3	--	--	--	218.3
Other comprehensive earnings:							
Foreign currency translation adjustments	--	--	--	--	--	24.8	24.8
Tax effect of other comprehensive loss adjustments	--	--	--	--	--	(9.9)	(9.9)
Comprehensive earnings							233.2
Issuance of common stock under employee stock plans	0.2	66.1	--	--	--	--	66.3
Issuance of restricted stock awards	--	--	--	--	--	--	--
Surrender of restricted stock awards	--	--	--	(3.1)	--	--	(3.1)
Cancellation of restricted stock awards	--	--	--	--	--	--	--

Edgar Filing: LABORATORY CORP OF AMERICA HOLDINGS - Form 10-Q

	Common Stock	Additional Paid-in Capital	Retained Earnings	Treasury Stock	Unearned Restricted Stock Compensation	Accumulated Other Comprehensive Earnings	Total Shareholders' Equity
Reversal of unamortized deferred compensation balance	--	(6.9)	--	--	6.9	--	--
Stock compensation	--	20.2	--	--	--	--	20.2
Income tax benefit from stock options exercised	--	15.7	--	--	--	--	15.7
Purchase of common stock	(0.3)	(207.6)	--		--	--	(207.9)
BALANCE AT JUNE 30, 2006	\$ 14.7	\$ 1,227.2	\$ 1,554.6	\$ (891.6)	\$ --	\$ 105.2	\$ 2,010.1

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS

(in millions)
(unaudited)

	Six Months Ended June 30,	
	2006	2005
CASH FLOWS FROM OPERATING ACTIVITIES:		
Net earnings	\$ 218.3	\$ 202.6
Adjustments to reconcile net earnings to net cash provided by operating activities:		
Depreciation and amortization	77.1	73.1
Stock compensation	20.2	6.5
Loss on sale of assets	0.6	0.2
Investment loss	--	3.1
Accreted interest on zero coupon- subordinated notes	5.4	5.3
Cumulative earnings in excess of distribution from joint venture partnerships	(1.6)	(5.5)
Deferred income taxes	6.0	1.2
Change in assets and liabilities (net of effects of acquisitions):		
Increase in accounts receivable, net	(43.6)	(37.8)
(Increase)decrease in inventories	(10.8)	5.8
(Increase)decrease in prepaid expenses and other	(1.1)	0.8
Increase(decrease) in accounts payable	7.6	(10.1)
Increase(decrease) in accrued expenses and other	29.0	(4.3)
	<u>307.1</u>	<u>240.9</u>
CASH FLOWS FROM INVESTING ACTIVITIES:		
Capital expenditures	(42.4)	(45.7)
Proceeds from sale of assets	0.9	0.8
Deferred payments on acquisitions	(2.3)	(2.4)
Purchases of short-term investments	(552.9)	(572.0)
Proceeds from sale of short-term investments	384.9	718.2
Acquisition of licensing technology	(0.5)	(6.2)
Acquisition of business, net of cash acquired	(1.8)	(323.2)
	<u>(214.1)</u>	<u>(230.5)</u>
CASH FLOWS FROM FINANCING ACTIVITIES:		
Proceeds from revolving credit facilities	50.0	135.0
Payments on revolving credit facilities	(50.0)	(78.0)
Bank overdraft	30.4	--
Payments on long-term debt	(1.2)	(0.1)
Payments on long-term lease obligations	(1.5)	(1.4)
Excess tax benefits from stock based compensation	6.3	--
Net proceeds from issuance of stock to employees	66.3	40.2
Purchase of common stock	(222.9)	(132.1)
	<u>(122.6)</u>	<u>(36.4)</u>
Net cash used for financing activities		
	<u>0.8</u>	<u>(0.4)</u>
Effect of exchange rate changes on cash and cash equivalents		

Edgar Filing: LABORATORY CORP OF AMERICA HOLDINGS - Form 10-Q

	Six Months Ended	
	June 30,	
Net decrease in cash and cash equivalents	(28.8)	(26.4)
Cash and cash equivalents at beginning of period	45.4	47.6
	<u> </u>	<u> </u>
Cash and cash equivalents at end of period	\$ 16.6	\$ 21.2
	<u> </u>	<u> </u>

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(dollars and shares in millions, except per share data)

1. BASIS OF FINANCIAL STATEMENT PRESENTATION

The consolidated financial statements include the accounts of Laboratory Corporation of America Holdings (the Company) and its majority-owned subsidiaries over which it exercises control. Long-term investments in affiliated companies in which the Company owns greater than 20%, and therefore exercises significant influence, but which it does not control, are accounted for using the equity method. Investments in which the Company does not exercise significant influence (generally, when the Company has an investment of less than 20% and no representation on the investee's Board of Directors) are accounted for using the cost method. All significant inter-company transactions and accounts have been eliminated. The Company does not have any variable interest entities or special purpose entities whose financial results are not included in the condensed consolidated financial statements.

The Company has a cash management system under which a cash overdraft exists for uncleared checks in the Company's primary disbursement accounts. The cash amount in the accompanying financial statements represents book balances excluding the effect of the uncleared checks which were \$30.4 and included in accounts payable at June 30, 2006.

The financial statements of the Company's foreign subsidiaries are measured using the local currency as the functional currency. Assets and liabilities are translated at exchange rates as of the balance sheet date. Revenues and expenses are translated at average monthly exchange rates prevailing during the period. Resulting translation adjustments are included in Accumulated other comprehensive earnings.

The accompanying condensed consolidated financial statements of the Company are unaudited. In the opinion of management, all adjustments necessary for a fair presentation of such financial statements have been included. Except as otherwise disclosed, all such adjustments are of a normal recurring nature. Interim results are not necessarily indicative of results for a full year. The year-end condensed consolidated balance sheet data was derived from audited financial statements but does not include all disclosures required by generally accepted accounting principles.

The financial statements and notes are presented in accordance with the rules and regulations of the Securities and Exchange Commission and do not contain certain information included in the Company's 2005 annual report on Form 10-K. Therefore, the interim statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company's annual report.

Financial Statement Revision

Certain prior year amounts in the Company's Condensed Consolidated Statement of Cash Flows have been revised based on the Company's change in presentation of auction rate securities (ARS) and variable rate demand notes (VRDN) as short-term investments instead of cash and equivalents. The aggregate purchases and proceeds from the sale of these securities for the six months ended June 30, 2005 should have been presented in the consolidated statements of cash flows from investing activities for those years. These revisions had no impact on the Company's 2005 results of operations, changes in shareholders' equity, or cash flows from operating activities and financing activities.

ARS and VRDN do not meet the definition of a cash equivalent as defined in SFAS No. 95, Statement of Cash Flows (SFAS 95) as such securities have maturity dates greater than 90 days. ARS and VRDN are variable bonds tied to short-term interest rates with maturities on the face of the securities in excess of 90 days. ARS and VRDN have interest rate resets through a modified Dutch auction, at predetermined short-term intervals, usually every 1, 7, or 35 days. The Company had historically classified ARS and VRDN as cash and cash equivalents if the period between the interest rate resets was 90 days or less, which was based on the Company's ability to either liquidate its holdings or roll its investments over to the next reset period. The Company reevaluated the classification of these investments considering the maturity dates associated with the underlying bonds. The effects of this revision are summarized in the table below.

LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(dollars and shares in millions, except per share data)

	Six Months Ended June 30, 2005	
	As Originally Reported	As Revised
	Cash flow from investing activities:	
Purchases of short-term investments	\$ --	\$ (572.0)
Proceeds from sale of short-term investments	20.0	718.2
Net cash used for investing activities	(356.7)	(230.5)
Net decrease in cash and cash equivalents	(152.6)	(26.4)
Cash and cash equivalents at beginning of period	186.8	47.6
Cash and cash equivalents at end of period	34.2	21.2

As of June 30, 2006, the Company had \$185.7 of ARS and VRDN classified as short-term investments.

2. EARNINGS PER SHARE

Basic earnings per share is computed by dividing net earnings by the weighted average number of common shares outstanding. Diluted earnings per share is computed by dividing net earnings including the impact of dilutive adjustments by the weighted average number of common shares outstanding plus potentially dilutive shares, as if they had been issued at the beginning of the period presented. Potentially dilutive common shares result primarily from the Company's outstanding stock options, restricted stock awards, performance share awards, and shares issuable upon conversion of zero-coupon subordinated notes.

The following represents a reconciliation of basic earnings per share to diluted earnings per share:

	Three Months Ended June 30,						Six Months Ended June 30,					
	2006			2005			2006			2005		
	Income	Shares	Per Share Amount	Income	Shares	Per Share Amount	Income	Shares	Per Share Amount	Income	Shares	Per Share Amount
Basic earnings per share:												
Net earnings	\$ 116.4	124.3	\$ 0.94	\$ 106.0	134.2	\$ 0.79	\$ 218.3	124.4	\$ 1.75	\$ 202.6	134.4	\$ 1.51
Dilutive effect of employee stock plans and other	--	2.0		--	1.3		--	2.2		--	1.2	
Effect of convertible debt, net of tax	1.7	10.0		1.6	10.0		3.3	10.0		3.2	10.0	
Diluted earnings per share:												
Net earnings including impact of dilutive adjustments	\$ 118.1	136.3	\$ 0.87	\$ 107.6	145.5	\$ 0.74	\$ 221.6	136.6	\$ 1.62	\$ 205.8	145.6	\$ 1.41

The following table summarizes the potential common shares not included in the computation of diluted earnings per share because their impact would have been antidilutive:

Three Months Ended June 30,	Six Months Ended June 30,
--------------------------------	------------------------------

	Three Months Ended		Six Months Ended	
	June 30,		June 30,	
	2006	2005	2006	2005
Stock options	1.3	--	1.0	--
3. STOCK COMPENSATION PLANS				

There are currently 19.7 shares authorized for issuance under the 2000 Stock Incentive Plan and the Amended and Restated 1999 Stock Incentive Plan. Each of these

8

LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(dollars and shares in millions, except per share data)

plans was approved by shareholders. At June 30, 2006, there were 2.1 shares available for grant under the Company's stock option plans.

Effective January 1, 2006, the Company adopted Statement of Financial Accounting Standards No. 123 (revised 2004), Share-Based Payment (SFAS 123(R)), which requires the Company to measure the cost of employee services received in exchange for all equity awards granted, based on the fair market value of the award as of the grant date. SFAS 123(R) supersedes Statement of Financial Accounting Standards No. 123, Accounting for Stock-Based Compensation and Accounting Principles Board Opinion No. 25, Accounting for Stock Issued to Employees (APB 25). The Company has adopted SFAS 123(R) using the modified prospective application method of adoption which requires the Company to record compensation cost related to unvested stock awards as of December 31, 2005 by recognizing the unamortized grant date fair value of these awards over the remaining service periods of those awards with no change in historical reported earnings. Awards granted after December 31, 2005 are valued at fair value in accordance with provisions of SFAS 123(R) and recognized on a straight line basis over the service periods of each award. The Company estimated forfeiture rates for the first six months of 2006 based on its historical experience.

Prior to 2006, the Company accounted for stock-based compensation in accordance with APB 25 using the intrinsic value method, which did not require that compensation cost be recognized for the Company's stock option and stock purchase plans provided the option exercise price was established at the common stock fair market value on the date of grant. Under APB 25, the Company was required to record expense over the vesting period for the value of its restricted stock and performance share awards. Prior to 2006, the Company provided pro forma disclosure amounts in accordance with SFAS No. 148, Accounting for Stock-Based Compensation Transition and Disclosure (SFAS No. 148), as if the fair value method defined by SFAS No. 123 had been applied to all of its stock-based compensation.

As a result of adopting SFAS 123(R), the Company's net earnings were reduced by \$3.2 and \$6.7 for the three and six months ended June 30, 2006, respectively. The impact on basic and diluted earnings per share for the three months ended June 30, 2006 was \$0.03 and \$0.02 per share, respectively. The impact on basic and diluted earnings per share for the six months ended June 30, 2006 was \$0.05 and \$0.05 per share, respectively.

The following tables summarize the components of the Company's stock-based compensation programs recorded as expense for the three and six months ended June 30, 2006:

	Three Months Ended					
	June 30, 2006			June 30, 2005		
	Pre-tax Compensation Expense	Tax Benefit	Net	Pre-tax Compensation Expense	Tax Benefit	Net
Stock option and stock purchase plans	\$ 5.4	\$ (2.2)	\$ 3.2	\$ --	\$ --	\$ --
Restricted stock and performance share awards	3.8	(1.6)	2.2	3.4	(1.4)	2.0
Total share based compensation	\$ 9.2	\$ (3.8)	\$ 5.4	\$ 3.4	\$ (1.4)	\$ 2.0

	Six Months Ended					
	June 30, 2006			June 30, 2005		
	Pre-tax Compensation Expense	Tax Benefit	Net	Pre-tax Compensation Expense	Tax Benefit	Net

Edgar Filing: LABORATORY CORP OF AMERICA HOLDINGS - Form 10-Q

Six Months Ended

Stock option and stock purchase plans	\$ 11.3	\$ (4.6)	\$ 6.7	\$ --	\$ --	\$ --
Restricted stock and performance share awards	<u>8.9</u>	<u>(3.6)</u>	<u>5.3</u>	<u>6.5</u>	<u>(2.7)</u>	<u>3.8</u>
Total share based compensation	<u>\$ 20.2</u>	<u>\$ (8.2)</u>	<u>\$ 12.0</u>	<u>\$ 6.5</u>	<u>\$ (2.7)</u>	<u>\$ 3.8</u>

9

LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(dollars and shares in millions, except per share data)

The following table shows the pro forma net income for the three and six months ended June 30, 2005 as if the fair value based method had been applied to all awards:

	Three Months Ended June 30, 2005	Six Months Ended June 30, 2005
Net earnings, as reported	\$ 106.0	\$ 202.6
Add: Stock-based compensation recorded as expense, net of related tax effects	2.0	3.8
Deduct: Total stock-based compensation determined under fair value method for all awards, net of related tax effects	(6.4)	(12.5)
Pro forma net income	\$ 101.6	\$ 193.9
Basic earnings per common share		
As reported	\$ 0.79	\$ 1.51
Pro forma	0.76	1.44
Diluted earnings per common share		
As reported	\$ 0.74	\$ 1.41
Pro forma	0.71	1.35

Stock Options

Stock options are generally granted at an exercise price equal to or greater than the fair market price per share on the date of grant. Also, for each grant, options vest ratably over a period of three years on the anniversaries of the grant date, subject to their earlier expiration or termination.

Stock option activity under the Company's stock option plan for the six months ended June 30, 2006 were as follows:

	Number of Options	Weighted- Average Exercise Price per Option	Weighted- Average Remaining Contractual Term	Aggregate Intrinsic Value
Outstanding at January 1, 2006	6.0	\$ 38.10		
Granted	1.4	58.58		
Exercised	(1.7)	36.15		
Cancelled	(0.2)	49.73		
Outstanding at June 30, 2006	5.5	\$ 43.56	7.5	\$ 103.3
Vested and expected to vest at June 30, 2006	5.3	\$ 43.03	7.4	\$ 101.1
Exercisable at June 30, 2006	2.9	\$ 36.35	6.2	\$ 74.4

The aggregate intrinsic value in the table above represents the total pre-tax intrinsic value (the difference between the Company's closing stock price on the last trading day of the second quarter of 2006 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on June 30, 2006. The amount of intrinsic value will change based on the fair market value of the Company's stock.

Edgar Filing: LABORATORY CORP OF AMERICA HOLDINGS - Form 10-Q

LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(dollars and shares in millions, except per share data)

Cash received by the Company from option exercises, the actual tax benefit realized for the tax deductions and the aggregate intrinsic value of options exercised from option exercises under all share-based payment arrangements during the three and six months ended June 30, 2006 and 2005 were as follows:

	Three Months Ended June 30,		Six Months Ended June 30,	
	2006	2005	2006	2005
Cash received by the Company	\$ 16.1	\$ 16.7	\$ 61.9	\$ 31.5
Tax benefits realized	\$ 4.3	\$ 4.2	\$ 14.5	\$ 7.3
Aggregate intrinsic value	\$ 10.9	\$ 10.5	\$ 36.8	\$ 18.3

The following table shows the weighted average grant-date fair values of options and the weighted average assumptions that the Company used to develop the fair value estimates:

	Six Months Ended June 30,	
	2006	2005
Fair value per option	\$ 12.24	\$ 16.49
Valuation assumptions		
Weighted average expected life (in years)	3.1	3.1
Risk free interest rate	4.4%	3.5%
Expected volatility	21.5%	45.3%
Expected dividend yield	0.0%	0.0%

The Black Scholes model incorporates assumptions to value stock-based awards. The risk-free interest rate for periods within the contractual life of the option is based on a zero-coupon U.S. government instrument over the contractual term of the equity instrument. Expected volatility of the Company's stock is based on historical volatility of the Company's stock. The Company uses historical data to calculate the expected life of the option. Groups of employees and non-employee directors that have similar exercise behavior with regard to option exercise timing and forfeiture rates are considered separately for valuation purposes.

Restricted Stock and Performance Shares

The fair value of restricted stock and performance share awards (nonvested shares) is determined based on the closing price of the Company's common stock on the day immediately preceding the grant date. The weighted-average grant date fair value of non-vested shares granted during the six months ended June 30, 2006 and 2005 was \$58.60 and \$47.93, respectively.

The following table shows a summary of nonvested shares for the six months ended June 30, 2006:

	Number of Shares	Weighted- Average Grant Date Fair Value
Nonvested at January 1, 2006	1.0	\$ 45.16
Granted	0.2	58.60
Vested	(0.2)	41.62
Adjustments	0.1	48.10
Nonvested at June 30, 2006	1.1	48.01

Number of Shares	Weighted- Average Grant Date Fair Value
-----------------------------	--

11

LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(dollars and shares in millions, except per share data)

As of June 30, 2006, there was \$27.4 of total unrecognized compensation cost related to nonvested restricted stock and performance share-based compensation arrangements granted under the stock incentive plans. That cost is expected to be recognized over a weighted average period of 2.0 years.

4. GOODWILL AND INTANGIBLE ASSETS

The changes in the carrying amount of goodwill (net of accumulated amortization) for the six-month period ended June 30, 2006 and for the year ended December 31, 2005 are as follows:

	June 30, 2006	December 31, 2005
Balance as of January 1	\$ 1,477.0	\$ 1,300.4
Goodwill acquired during the period	1.0	171.0
Adjustments to goodwill	(1.6)	5.6
Balance at end of period	<u>\$ 1,476.4</u>	<u>\$ 1,477.0</u>

The components of identifiable intangible assets are as follows:

	June 30, 2006		December 31, 2005	
	Gross Carrying Amount	Accumulated Amortization	Gross Carrying Amount	Accumulated Amortization
Customer lists	\$ 677.2	\$ (198.3)	\$ 675.8	\$ (181.6)
Patents, licenses and technology	88.9	(33.0)	88.5	(28.0)
Non-compete agreements	25.7	(23.3)	25.6	(22.5)
Trade name	100.7	(16.2)	100.7	(12.8)
	<u>\$ 892.5</u>	<u>\$ (270.8)</u>	<u>\$ 890.6</u>	<u>\$ (244.9)</u>

Amortization of intangible assets for the six month and three month periods ended June 30, 2006 was \$26.0 and \$13.0, respectively, and \$25.2 and \$13.1 for the six month and three month periods ended June 30, 2005, respectively. Amortization expense for the net carrying amount of intangible assets is estimated to be \$25.6 for the remainder of fiscal 2006, \$49.8 in fiscal 2007, \$47.2 in fiscal 2008, \$46.2 in fiscal 2009, \$43.9 in fiscal 2010 and \$409.0 thereafter.

5. DEBT

Short-term borrowings and current portion of long-term debt at June 30, 2006 and December 31, 2005 consisted of the following:

	June 30, 2006	December 31, 2005
Zero coupon convertible subordinated notes	\$ 549.9	\$ 544.4
Current portion of long-term debt	--	0.2
Total short-term borrowings and current portion of long term debt	<u>\$ 549.9</u>	<u>\$ 544.6</u>

**June 30,
2006**

**December 31,
2005**

12

LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(dollars and shares in millions, except per share data)

Long term debt at June 30, 2006 and December 31, 2005 consisted of the following:

	<u>June 30, 2006</u>	<u>December 31, 2005</u>
Senior notes due 2013	\$ 352.8	\$ 353.0
Senior notes due 2015	250.0	250.0
Other long-term debt	0.5	1.5
Total long-term debt	<u>\$ 603.3</u>	<u>\$ 604.5</u>

Revolving Credit Facility

There were no balances outstanding on the Company's revolving credit facility at June 30, 2006 and December 31, 2005. The revolving credit facility bears interest at varying rates based upon the Company's credit rating with Standard & Poor's Ratings Services. As of June 30, 2006, the weighted average interest rate on the revolving credit facility was 5.81%. The revolving credit facility contains certain debt covenants which require that the Company maintain certain financial ratios. The Company was in compliance with all covenants at June 30, 2006.

6. PREFERRED STOCK AND COMMON SHAREHOLDERS' EQUITY

The Company is authorized to issue up to 265.0 shares of common stock, par value \$0.10 per share. The Company's treasury shares are recorded at aggregate cost. The Company is authorized to issue up to 30.0 shares of preferred stock, par value \$0.10 per share. There are no preferred shares outstanding as of June 30, 2006.

The changes in common shares issued and held in treasury are summarized below:

	<u>Issued</u>	<u>Held in Treasury</u>	<u>Outstanding</u>
Common shares at December 31, 2005	148.0	(21.5)	126.5
Common stock issued under employee stock plans	2.0	--	2.0
Surrender of restricted stock awards	--	(0.1)	(0.1)
Retirement of common stock	(3.3)	--	(3.3)
Common shares at June 30, 2006	<u>146.7</u>	<u>(21.6)</u>	<u>125.1</u>

Share Repurchase Program

During the six months ended June 30, 2006, the Company purchased 3.3 shares of its common stock at a cost of \$185.0. As of June 30, 2006, the Company had outstanding authorizations from the Board of Directors to purchase approximately \$100.2 of Company common stock.

On December 7, 2005, the Company executed an overnight share repurchase transaction with a bank for the acquisition of 4.8 shares of the Company's outstanding common stock for an initial purchase price of \$52.04 per share. The transaction was financed with borrowings under the Company's revolving line of credit. The Company used cash on hand and the proceeds of the Senior Notes due 2015 to repay borrowings under the Company's revolving credit facility. Pursuant to the agreement with the bank, the bank purchased 4.8 shares in the open market over the period ended June 13, 2006. At the end of the purchase period, the Company made a cash payment of \$22.9 to the bank to settle its obligation for the purchase price adjustment based on the volume weighted average purchase price of the shares acquired compared to the initial purchase price. Such price adjustment was payable either in cash or common stock at the discretion of the Company. The total cost of the initial purchase was approximately \$251.7, including a \$1.5 cap premium and \$0.2 in commissions and other fees. The shares repurchased under the overnight share repurchase agreement were immediately canceled and returned to the status of authorized but unissued shares. The Company reduced common stock and additional paid in capital by

LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(dollars and shares in millions, except per share data)

approximately \$0.5 and \$251.2, respectively to record the initial purchase price. The forward contract associated with the overnight share repurchase transaction was accounted for in accordance with EITF 00-19, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company's Own Stock, as an equity instrument. The \$22.9 paid in connection with the price adjustment was recorded as a reduction to additional paid in capital. The diluted net income per share calculation for the three and six months ended June 30, 2006 includes the potential shares of common stock that could have been issued to settle the overnight share repurchase transaction.

7. NEW ACCOUNTING PRONOUNCEMENTS

In May 2005, the FASB issued SFAS No. 154 Accounting Changes and Error Corrections (SFAS No. 154), which is effective for periods beginning after December 15, 2005. This statement replaces APB Opinion No. 20 Accounting Changes (APB 20) and SFAS No. 3 Reporting Accounting Changes in Interim Financial Statements. APB 20 previously required that most voluntary changes in accounting principle be recognized by including, in net income of the period of the change, the cumulative effect of changing to the new accounting principle. SFAS No. 154 requires retrospective application to prior periods' financial statements of changes in accounting principle, unless it is impracticable to determine either the period specific effects or the cumulative effect of the change. The Company does not expect that this standard will impact its financial position or results of operations.

In July 2006, the FASB issued Financial Interpretation No. 48, Accounting for Uncertainty in Income Taxes an interpretation of SFAS No. 109 (FIN 48). FIN 48 clarifies the accounting for uncertainty in income taxes recognized in an enterprise's financial statements in accordance with SFAS No. 109, Accounting for Income Taxes. FIN 48 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. FIN 48 is effective for fiscal years beginning after December 15, 2006. The Company is currently evaluating the impact, if any, of FIN 48 on its financial statements.

8. COMMITMENTS AND CONTINGENCIES

On June 24, 2003, the Company and certain of its executive officers were sued in the United States District Court for the Middle District of North Carolina in the first of a series of putative shareholder class actions alleging securities fraud. Shortly thereafter, five other complaints containing substantially identical allegations were filed against the Company and certain of the Company's executive officers. Each of the complaints alleged that the defendants violated the federal securities laws by making material misstatements and/or omissions that caused the price of the Company's stock to be artificially inflated between February 13 and October 3, 2002. The plaintiffs sought certification of a class of substantially all persons who purchased shares of the Company's stock during that time period and unspecified monetary damages. The six cases were consolidated and, on May 18, 2006, the Court granted the defendant's motion to dismiss the cases in their entirety, and the time to appeal the dismissal has expired.

The Company is the appellant in a patent case originally filed by Competitive Technologies, Inc. and Metabolite Laboratories, Inc. in the United States District Court for the District of Colorado. After a jury trial, the district court entered judgment against the Company for patent infringement, with total damages and attorney's fees payable by the Company of approximately \$7.8. The underlying judgment has been paid. The Company vigorously contested the judgment and appealed the case to the United States Court of Appeals for the Federal Circuit. On June 8, 2004, that court affirmed the judgment against the Company and, on August 5, 2004, the Company's request for rehearing was denied. On October 31, 2005, the United States Supreme Court granted the Company's petition for a writ of certiorari and the case was argued before the Supreme Court on March 21, 2006. On June 22, 2006, the Supreme Court dismissed the Company's appeal and the case has been remanded to the District Court for further proceedings relating to the plaintiffs' claims for post trial damages and clarification of the terms of the terms of the injunction. The Company does not expect the resolution of these issues to have a material adverse effect on its financial position, results of operations or liquidity.

The Company is also involved in various claims and legal actions arising in the ordinary course of business. These matters include, but are not limited to, intellectual property disputes, professional liability, employee related matters, and inquiries from governmental agencies and Medicare or Medicaid

LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(dollars and shares in millions, except per share data)

payers and managed care payers requesting comment on allegations of billing irregularities that are brought to their attention through billing audits or third parties. In the opinion of management, based upon the advice of counsel and consideration of all facts available at this time, the ultimate disposition of these matters is not expected to have a material adverse effect on the financial position, results of operations or liquidity of the Company. The Company is also named from time to time in suits brought under the *qui tam* provisions of the False Claims Act. These suits typically allege that the Company has made false statements and/or certifications in connection with claims for payment from federal health care programs. They may remain under seal (hence, unknown to the Company) for some time while the government decides whether to intervene on behalf of the *qui tam* plaintiff. Such claims are an inevitable part of doing business in the health care field today and, in the opinion of management, based upon the advice of counsel and consideration of all facts available at this time, the ultimate disposition of those *qui tam* matters presently known to the Company is not expected to have a material adverse effect on the financial position, results of operations or liquidity of the Company.

The Company believes that it is in compliance in all material respects with all statutes, regulations and other requirements applicable to its clinical laboratory operations. The clinical laboratory testing industry is, however, subject to extensive regulation, and the courts have not interpreted many of these statutes and regulations. There can be no assurance therefore that those applicable statutes and regulations would be interpreted or applied by a prosecutorial, regulatory or judicial authority in a manner that would not adversely affect the Company. Potential sanctions for violation of these statutes and regulations include significant fines and the loss of various licenses, certificates and authorizations.

Under the Company's present insurance programs, coverage is obtained for catastrophic exposure as well as those risks required to be insured by law or contract. The Company is responsible for the uninsured portion of losses related primarily to general, professional and vehicle liability, certain medical costs and workers' compensation. The self-insured retentions are on a per occurrence basis without any aggregate annual limit. Provisions for losses expected under these programs are recorded based upon the Company's estimates of the aggregated liability of claims incurred. At June 30, 2006 and December 31, 2005, the Company had provided letters of credit aggregating approximately \$62.5 and \$62.6 respectively, primarily in connection with certain insurance programs.

9. PENSION AND POSTRETIREMENT PLANS

Substantially all employees of the Company are covered by a defined benefit retirement plan (the Company Plan). The benefits to be paid under the Company Plan are based on years of credited service and average final compensation. The Company's policy is to fund the Company Plan with at least the minimum amount required by applicable regulations.

The Company has a second defined benefit retirement plan which covers its senior management group that provides for the payment of the difference, if any, between the amount of any maximum limitation on annual benefit payments under the Employee Retirement Income Security Act of 1974 and the annual benefit that would be payable under the Company Plan but for such limitation. This plan is an unfunded plan.

The effect on operations for both of the defined benefit retirement plans is summarized as follows:

	Three Months Ended June 30,		Six Months Ended June 30,	
	2006	2005	2006	2005
Service Cost for benefits earned	\$ 4.4	\$ 4.2	\$ 8.6	\$ 7.9
Interest Cost on benefit obligation	3.5	3.5	7.2	6.9
Expected return on plan assets	(5.3)	(5.4)	(10.7)	(10.3)
Net amortization and deferral	1.0	--	2.2	0.7
	<hr/>	<hr/>	<hr/>	<hr/>
Defined benefit retirement plan costs	\$ 3.6	\$ 2.3	\$ 7.3	\$ 5.2
	<hr/>	<hr/>	<hr/>	<hr/>

As of June 30, 2006, the Company has made no contributions to its defined benefit retirement plan.

LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(dollars and shares in millions, except per share data)

The Company has assumed obligations under a subsidiary's postretirement medical plan. Coverage under this plan is restricted to a limited number of existing employees of the subsidiary. This plan is unfunded and the Company's policy is to fund benefits as claims are incurred. The effect on operations of the postretirement medical plan is shown in the following table:

	Three Months Ended June 30,		Six Months Ended June 30,	
	2006	2005	2006	2005
Service Cost for benefits earned	\$ 0.1	\$ 0.1	\$ 0.3	\$ 0.3
Interest Cost on benefit obligation	0.6	0.6	1.1	1.3
Net amortization and deferral	(0.4)	(0.4)	(1.0)	(1.1)
Amortization of actuarial loss	(0.1)	(0.1)	--	0.2
	<u> </u>	<u> </u>	<u> </u>	<u> </u>
Postretirement benefit expense	\$ 0.2	\$ 0.2	\$ 0.4	\$ 0.7
	<u> </u>	<u> </u>	<u> </u>	<u> </u>

10. SUPPLEMENTAL CASH FLOW INFORMATION

	Six Months Ended June 30,	
	2006	2005
Supplemental schedule of cash flow information:		
Cash paid during period for:		
Interest	16.7	9.6
Income taxes, net of refunds	113.2	134.9

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

FORWARD-LOOKING STATEMENTS

The Company has made in this report, and from time to time may otherwise make in its public filings, press releases and discussions by Company management, forward-looking statements concerning the Company's operations, performance and financial condition, as well as its strategic objectives. Some of these forward-looking statements can be identified by the use of forward-looking words such as believes, expects, may, will, should, seeks, approximately, intends, plans, estimates, or anticipates or the negative of those words or other comparatives. Such forward-looking statements are subject to various risks and uncertainties and the Company claims the protection afforded by the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those currently anticipated due to a number of factors in addition to those discussed elsewhere herein and in the Company's other public filings, press releases and discussions with Company management, including:

1. changes in federal, state, local and third party payer regulations or policies (or in the interpretation of current regulations) affecting governmental and third-party reimbursement for clinical laboratory testing;
2. adverse results from investigations of clinical laboratories by the government, which may include significant monetary damages and/or exclusion from the Medicare and Medicaid programs;
3. loss or suspension of a license or imposition of a fine or penalties under, or future changes in, the law or regulations of the Clinical Laboratory Improvement Act of 1967, and the Clinical Laboratory Improvement Amendments of 1988, or those of Medicare, Medicaid, the False Claims Act or other federal, state or local agencies;
4. failure to comply with the Federal Occupational Safety and Health Administration requirements and the Needlestick Safety and Prevention Act, which could result in penalties and loss of licensure;
5. failure to comply with HIPAA, which could result in significant fines;
6. failure of third party payers to complete testing with the Company, or accept or remit transactions in HIPAA-required standard transaction and code set format, which could result in an interruption in the Company's cash flow;
7. increased competition, including price competition;
8. changes in payer mix, including an increase in capitated managed-cost health care or the impact of a shift to consumer-driven health plans;
9. failure to obtain and retain new customers and alliance partners, or a reduction in tests ordered or specimens submitted by existing customers;
10. failure to retain or attract managed care business as a result of changes in business models, including new risk based or network approaches, or other changes in strategy or business models by managed care companies;
11. failure to effectively manage the integration of newly acquired businesses and the cost related to such integration;
12. adverse results in litigation matters;
13. inability to attract and retain experienced and qualified personnel;
14. failure to maintain the Company's days sales outstanding levels;
15. decrease in credit ratings by Standard & Poor's and/or Moody's;

Edgar Filing: LABORATORY CORP OF AMERICA HOLDINGS - Form 10-Q

16. failure to develop or acquire licenses for new or improved technologies, or the use of new technologies by customers to perform their own tests;
17. inability to commercialize newly licensed tests or technologies or to obtain appropriate reimbursement for such tests, which could result in impairment in the value of certain capitalized licensing costs;
18. inability to obtain and maintain adequate patent and other proprietary rights for protection of the Company's products and services and successfully enforce the Company's proprietary rights;
19. the scope, validity and enforceability of patents and other proprietary rights held by third parties which might have an impact on the Company's ability to develop, perform, or market the Company's tests or operate its business;
20. failure in the Company's information technology systems resulting in an increase in testing turnaround time or a failure of billing processes or the failure to meet future regulatory or customer information technology and connectivity requirements;
21. failure of the Company's existing and new financial information systems resulting in failure to meet required financial reporting deadlines;
22. failure of the company's disaster recovery plans to provide adequate protection against the interruption of business and/or the recovery of business operations;
23. business interruption or other impact on the business due to adverse weather (including hurricanes), fires and/or other natural disasters and terrorism or other criminal acts;
24. failure by the Company to comply with the Sarbanes-Oxley Act of 2002, including Section 404 of that Act, which requires management to report on, and our independent registered public accounting firm to attest to and report on, our internal controls; and
25. liabilities that result from any future inability to comply with new corporate governance requirements.

18

RESULTS OF OPERATIONS (dollars in millions)

Three months ended June 30, 2006 compared with three months ended June 30, 2005

Net sales for the three months ended June 30, 2006 were \$903.7, an increase of \$50.4, or approximately 5.9%, from \$853.3 for the comparable 2005 period. The sales increase is a result of an increase of approximately 1.8% in accession volume (primarily volume growth in genomic and esoteric testing of 8.3% which was positively impacted by the acquisition of Esoterix, Inc. (Esoterix) in May 2005) and 4.1% in price. The improvement in pricing is a result of several factors, including our emphasis on pricing discipline and a continued shift in the Company's test mix in core, genomic and esoteric testing. Additionally, the acquisition of Esoterix positively impacted price.

Cost of sales, which includes primarily laboratory and distribution costs, was \$510.9 for the three months ended June 30, 2006 compared to \$488.4 in the corresponding 2005 period, an increase of \$22.5, or 4.6%. The increase in cost of sales is primarily the result of increased volume in genomic and esoteric testing and the acquisition discussed above. Cost of sales as a percentage of net sales was 56.5% for the three months ended June 30, 2006 and 57.2% in the corresponding 2005 period.

Selling, general and administrative expenses increased to \$190.2 for the three months ended June 30, 2006 from \$178.7 in the same period in 2005. As a percentage of net sales, selling, general and administrative expenses were 21.0% and 20.9% for the three months ended June 30, 2006 and 2005, respectively. This increase in selling, general and administrative expenses as a percentage of net sales is primarily the result of the Company's adoption of SFAS 123(R) during the first quarter of 2006, which required the Company to record compensation expense of \$5.4 related to its stock option and stock purchase plans, as well as the Company's investment in its sales force. These increases were partially offset by a reduction in the Company's effective bad debt expense rate.

The amortization of intangibles and other assets was \$13.0 and \$13.1 for the three months ended June 30, 2006 and 2005, respectively.

The investment loss of \$3.1 in 2005 relates to a write-off of the value of warrants to purchase common stock of Exact Sciences Corporation (Exact), which were obtained as part of the Company's licensing agreement for Exact's PreGen Plus technology in 2002. The original term of the warrants expired in June 2005.

Interest expense was \$11.6 for the three months ended June 30, 2006 compared with \$8.6 for the same period in 2005. The increase in interest expense is the result of interest on the Company's 5.625% Senior Notes which were issued in December 2005.

Income from investments in joint venture partnerships was \$17.9 for the three months ended June 30, 2006 compared with \$13.9 for the same period in 2005. This income represents the Company's ownership share in joint venture partnerships. A significant portion of this income is derived from investments in Ontario and Alberta, Canada, and is earned in Canadian dollars.

The provision for income taxes as a percentage of earnings before taxes was 40.6% for the three months ended June 30, 2006 compared to 39.7% for the three months ended June 30, 2005. The effective tax rate in 2005 was favorably impacted by a deduction for certain dividends received in 2005.

Six months ended June 30, 2006 compared with six months ended June 30, 2005.

Net sales for the six months ended June 30, 2006 were \$1,782.2, an increase of \$129.8, or 7.9%, from \$1,652.4 for the same period in 2005. The sales increase is a result of an increase of approximately 3.2% in accession volume (primarily volume growth in genomic and esoteric testing of 10.4% and 1.5% in the routine testing business). Price increased by 4.7% during the first six months. The improvement in pricing is a result of several factors, including our emphasis on pricing discipline, a continued shift in the Company's test mix in core, genomic and esoteric testing, and the acquisitions of Esoterix in May 2005 and US Pathology Labs, Inc. and Subsidiaries (US LABS) in February 2005.

Cost of sales, which includes primarily laboratory and distribution costs, was \$1,016.7 for the six months ended June 30, 2006 compared to \$949.2 for the same period of 2005, an increase of \$67.5, or 7.1%. The increase in cost of sales is primarily the result of increased volume in genomic and esoteric testing and the acquisitions discussed above. Cost of sales as a percentage of net sales was 57.0% for the six months ended June 30, 2006 and 57.4% for the same period in 2005.

Edgar Filing: LABORATORY CORP OF AMERICA HOLDINGS - Form 10-Q

Selling, general and administrative expenses increased to \$381.1 for the six months ended June 30, 2006 from \$347.3 for the same period in 2005. As a percentage of net sales, selling, general and administrative expenses were 21.4% and 21.0% for the six months ended June 30, 2006 and 2005, respectively. This increase in selling, general and administrative expenses as a percentage of net sales is primarily the result of the Company's adoption of SFAS 123(R) during the first quarter of 2006, which required the Company to record compensation expense of \$11.3 related to its stock option and stock purchase plans, as well as the Company's investment in its sales force. These increases were partially offset by a reduction in the Company's effective bad debt expense rate.

The amortization of intangibles and other assets was \$26.0 and \$25.2 for the six months ended June 30, 2006 and 2005. The increase in the amortization expense for the six months ended June 30, 2006 is a result of business acquisitions.

The investment loss of \$3.1 in 2005 relates to a write-off of the value of warrants to purchase common stock of Exact Sciences Corporation (Exact), which were obtained as part of the Company's licensing agreement for Exact's PreGen Plus technology in 2002. The original term of the warrants expired in June 2005.

Interest expense was \$23.5 for the six months ended June 30, 2006 compared with \$17.1 for the same period in 2005. The increase in interest expense is the result of interest on the Company's 5.625% Senior Notes which were issued in December 2005.

Income from investments in joint venture partnerships was \$33.3 for the six months ended June 30, 2006 compared with \$27.6 for the same period in 2005. This income represents the Company's ownership share in joint venture partnerships. A significant portion of this income is derived from investments in Ontario and Alberta, Canada, and is earned in Canadian dollars.

The provision for income taxes as a percentage of earnings before taxes was 40.7% for the six months ended June 30, 2006 compared to 40.2% for the six months ended June 30, 2005. The effective tax rate was favorably impacted by a deduction for certain dividends received in 2005.

LIQUIDITY AND CAPITAL RESOURCES (dollars and shares in millions)

Net cash provided by operating activities was \$307.1 and \$240.9 for the six months ended June 30, 2006 and 2005, respectively. The increase in cash flows primarily resulted from strong cash collections relative to the increase in net earnings plus lower tax payments.

Capital expenditures were \$42.4 and \$45.7 at June 30, 2006 and 2005, respectively. The Company expects total capital expenditures of approximately \$95.0 to \$110.0 in 2006. These expenditures are intended to support the Company's strategic initiatives centered around customer retention, scientific differentiation and managed care. In addition, the Company continues to make important investments in information technology connectivity with its customers and financial systems. Such expenditures are expected to be funded by cash flow from operations as well as borrowings under the Company's revolving credit facilities.

During the six months ended June 30, 2006, the Company repurchased \$185.0 of stock representing 3.3 shares. As of June 30, 2006, the Company had outstanding authorizations to purchase approximately \$100.2 of Company common stock.

Holder of the zero coupon-subordinated notes may require the Company to purchase in cash all or a portion of their notes on September 11, 2006 and 2011 at prices of \$741.92 to \$819.54 per note, respectively. The required cash payment on September 11, 2006 if all holders put their notes back to the Company would be \$552.0. Should the holders put the notes to the Company on either of the dates above, the Company believes that it will be able to satisfy this contingent obligation with cash on hand, borrowings on the revolving credit facility, and additional financing if necessary.

Based on current and projected levels of operations, coupled with availability under its revolving credit facilities, the Company believes it has sufficient liquidity to meet both its short-term and long-term cash needs.

ITEM 3. Quantitative and Qualitative Disclosure about Market Risk

The Company addresses its exposure to market risks, principally the market risk associated with changes in interest rates, through a controlled program of risk management that has included in the past, the use of derivative financial instruments such as interest rate swap agreements. Although, as set forth below, the Company's zero coupon-subordinated notes contain features that are considered to be embedded derivative instruments, the Company does not hold or issue derivative financial instruments for trading purposes. The Company does not believe that its exposure to market risk is material to the Company's financial position or results of operations.

The Company's zero coupon-subordinated notes contain the following two features that are considered to be embedded derivative instruments under SFAS No. 133 Accounting for Derivative Instruments and Hedging Activities :

- 1) The Company will pay contingent cash interest on the zero coupon-subordinated notes after September 11, 2006, if the average market price of the notes equals 120% or more of the sum of the issue price, accrued original issue discount and contingent additional principal, if any, for a specified measurement period.
- 2) Holders may surrender zero coupon-subordinated notes for conversion during any period in which the rating assigned to the zero coupon-subordinated notes by Standard & Poor's Ratings Services is BB- or lower.

Based upon independent appraisals, these embedded derivatives had no fair value at June 30, 2006.

ITEM 4. Controls and Procedures

As of the end of the period covered by the Form 10-Q, the Company carried out, under the supervision and with the participation of the Company's management, including the Company's Chief Executive Officer and Chief Financial Officer, an evaluation of the effectiveness of the design and operation of the Company's disclosure controls and procedures. Based on the foregoing, the Company's Chief Executive Officer and Chief Financial Officer concluded that the Company's disclosure controls and procedures are effective as of June 30, 2006.

There were no changes in the Company's internal control over financial reporting that occurred during the quarter ended June 30, 2006 that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES

PART II OTHER INFORMATION

Item 1. Legal Proceedings

See Note 8 to the Company's Unaudited Condensed Consolidated Financial Statements for the three and six months ended June 30, 2006, which is incorporated by reference.

Item 1A. Risk Factors

Information regarding risk factors appears in Management's Discussion and Analysis of Financial Condition and Results of Operations Information Related to Forward-Looking Statements, in Part I Item 2 of this Form 10-Q and in Part I Item 1A of the Company's Annual Report on Form 10-K for the year ended December 31, 2005. There have been no material changes from the risk factors previously disclosed in the Company's Annual Report on Form 10-K.

Item 2. Changes in Securities, Use of Proceeds and Issuer Purchases of Equity Securities
(Shares and dollars in millions, except per share data)

On December 7, 2005, the Company executed an overnight share repurchase transaction with a bank for the acquisition of 4.8 shares of the Company's outstanding common stock for an initial purchase price of \$52.04 per share. Pursuant to the agreement with the bank, the bank purchased 4.8 shares in the open market over the period ended June 13, 2006. At the end of the purchase period, the Company made a cash payment of \$22.9 million to the bank to settle its obligation for the purchase price adjustment based on the volume weighted average purchase price of the shares acquired compared to the initial purchase price. The diluted net income per share calculation for the three and six months ended June 30, 2006 includes the potential shares of common stock that may have been issued to settle the overnight share repurchase transaction.

As of June 30, 2006, the Company had outstanding authorizations from the Board of Directors to purchase approximately \$100.2 of Company common stock.

Item 4. Submission of Matters to a Vote of Security Holders

The following votes were provided by American Stock Transfer & Trust Company in their proxy tabulation reports dated May 24, 2006, reflecting voting activity through May 17, 2006:

Total outstanding shares of Laboratory Corporation of America Holdings (NEW): (excludes 2,009,472 non-voting Treasury shares)	124,676,025
--	-------------

Total shares voted:	113,692,691
---------------------	-------------

	<u>Votes</u> <u>For</u>	<u>Votes</u> <u>Withheld</u>
Election of the members of the Board of Directors:		
Thomas P. Mac Mahon	110,440,358	3,252,333
Kerri B. Anderson	112,788,521	904,170
Jean-Luc Bélingard	91,513,025	22,179,666
Wendy E. Lane	110,602,326	3,090,365
Robert E. Mittelstaedt, Jr.	112,780,613	912,078

Edgar Filing: LABORATORY CORP OF AMERICA HOLDINGS - Form 10-Q

Arthur H. Rubenstein, MBBCh	112,785,993	906,698
Andrew G. Wallace, MD	109,943,712	3,748,979
M. Keith Weikel	112,788,514	904,177

<u>Votes</u>	<u>Votes</u>	<u>Votes</u>
<u>For</u>	<u>Against</u>	<u>Abstained</u>
Approval of the amendment to the 1995 Stock		

Plan for Non-Employee Directors:	95,045,684	6,210,457	637,322
----------------------------------	------------	-----------	---------

22

Edgar Filing: LABORATORY CORP OF AMERICA HOLDINGS - Form 10-Q

<u>Votes</u> <u>For</u>	<u>Votes</u> <u>Against</u>	<u>Votes</u> <u>Abstained</u>	
Ratification of the appointment of			
PricewaterhouseCoopers LLP as the Company's			
independent accountants for the fiscal year			
ending December 31, 2006:			
	111,322,586	1,749,607	612,771

Total outstanding shares of Laboratory Corporation of America Holdings (OLD): 4,572
 Total shares voted: 421

	<u>Votes</u> <u>For</u>	<u>Votes</u> <u>Withheld</u>
Election of the members		
of the Board of Directors:		
Thomas P. Mac Mahon	421	0
Kerri B. Anderson	421	0
Jean-Luc Bélingard	421	0
Wendy E. Lane	421	0
Robert E. Mittelstaedt, Jr.	421	0
Arthur H. Rubenstein, MBBCh	421	0
Andrew G. Wallace, MD	421	0
M. Keith Weikel	421	0

<u>Votes</u> <u>For</u>	<u>Votes</u> <u>Against</u>	<u>Votes</u> <u>Abstained</u>	
Approval of the amendment to the 1995 Stock			
Plan for Non-Employee Directors:			
	421	0	296

<u>Votes</u> <u>For</u>	<u>Votes</u> <u>Against</u>	<u>Votes</u> <u>Abstained</u>	
Ratification of the appointment of			
PricewaterhouseCoopers LLP as the Company's			
independent accountants for the fiscal year			
ending December 31, 2006:			
	421	0	0

In addition, certain shares of National Health Laboratories Holdings Inc. (NHL) which have not been converted to Company shares were eligible to vote at the annual meeting and were voted as follows:

Total outstanding NHL shares: 28
 Total shares voted: 1

Edgar Filing: LABORATORY CORP OF AMERICA HOLDINGS - Form 10-Q

<u>Votes</u>	<u>Votes</u>
<u>For</u>	<u>Withheld</u>

Election of the members

of the Board of Directors:

Thomas P. Mac Mahon	1	0
Kerrii B. Anderson	1	0
Jean-Luc Bélingard	1	0
Wendy E. Lane	1	0
Robert E. Mittelstaedt, Jr.	1	0
Arthur H. Rubenstein, MBBCh	1	0
Andrew G. Wallace, MD	1	0
M. Keith Weikel	1	0

23

Edgar Filing: LABORATORY CORP OF AMERICA HOLDINGS - Form 10-Q

<u>Votes</u> <u>For</u>	<u>Votes</u> <u>Against</u>	<u>Votes</u> <u>Abstained</u>
Approval of the amendment to the 1995 Stock		
Plan for Non-Employee Directors:	1	0

<u>Votes</u> <u>For</u>	<u>Votes</u> <u>Against</u>	<u>Votes</u> <u>Abstained</u>
Ratification of the appointment of		
PricewaterhouseCoopers LLP as the Company's		
independent accountants for the fiscal year		
ending December 31, 2006:	1	0

Item 6. Exhibits

- (a) Exhibits
- 12.1* - Ratio of earnings to fixed charges
 - 31.1* - Certification by the Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a)
 - 31.2* - Certification by the Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a)
 - 32* - Written Statement of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350)

* filed herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

LABORATORY CORPORATION OF AMERICA HOLDINGS
Registrant

By: /s/ THOMAS P. MAC MAHON
Thomas P. Mac Mahon
Chairman, President
and Chief Executive Officer

By: /s/ WILLIAM B. HAYES
William B. Hayes
Executive Vice President,
Chief Financial Officer and
Treasurer

August 2, 2006